Nanologica AB Asset Resilience Ratio
Nanologica AB asset resilience ratio. Nanologica AB (NICA) has an Asset Resilience Ratio of 1.14% as of September 2022. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. See operational self-sufficiency of Nanologica AB to measure how many days the company can operate on defensive assets alone.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio of Nanologica AB (2018–2024)
Asset resilience ratio of Nanologica AB from 2018 to 2024. This chart shows how Nanologica AB's Asset Resilience Ratio has changed over time. Read Nanologica AB (NICA) total liabilities for a breakdown of total debt and financial obligations.
Liquid Assets Composition Over Time
This chart breaks down Nanologica AB's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For the complete balance sheet picture, see NICA current and non-current assets.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | Skr0.00 | 0% |
| Short-term Investments | Skr1.05 Million | 1.14% |
| Total Liquid Assets | Skr1.05 Million | 1.14% |
Asset Resilience Insights
- Limited Liquidity: Nanologica AB maintains only 1.14% of assets in liquid form.
- This low level may indicate efficient asset utilization but could pose risks during economic downturns.
- The company has significant short-term investments, indicating active treasury management.
Nanologica AB Industry Peers by Asset Resilience Ratio
Compare Nanologica AB's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Hyloris Developmentsen Sa
BR:HYL |
Biotechnology | 1.36% |
|
Biomarin Pharmaceutical Inc
NASDAQ:BMRN |
Biotechnology | 0.00% |
|
Oruka Therapeutics, Inc.
NASDAQ:ORKA |
Biotechnology | 53.11% |
|
Gempharmatech Co. Ltd. A
SHG:688046 |
Biotechnology | 23.95% |
|
Vor Biopharma Inc
NASDAQ:VOR |
Biotechnology | 74.48% |
|
Inventiva S.A
PA:IVA |
Biotechnology | 52.73% |
|
Sunmax Biotechnology Co Ltd
TWO:4728 |
Biotechnology | 10.53% |
|
Guangdong VTR Bio-Tech Co Ltd
SHE:300381 |
Biotechnology | 4.98% |
Nanologica AB Asset Resilience Ratio by Year (2018–2024)
Nanologica AB asset resilience ratio by year from 2018 to 2024. The table below shows the annual Asset Resilience Ratio data for Nanologica AB.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2024-12-31 | 0.00% | Skr-1.00K ≈ $-107.62 |
Skr143.10 Million ≈ $15.40 Million |
-0.73pp |
| 2021-12-31 | 0.73% | Skr714.00K ≈ $76.84K |
Skr98.32 Million ≈ $10.58 Million |
-0.38pp |
| 2020-12-31 | 1.10% | Skr1.61 Million ≈ $173.80K |
Skr146.34 Million ≈ $15.75 Million |
+1.10pp |
| 2019-12-31 | 0.00% | Skr1.00 ≈ $0.11 |
Skr42.29 Million ≈ $4.55 Million |
0.00pp |
| 2018-12-31 | 0.00% | Skr1.00 ≈ $0.11 |
Skr34.33 Million ≈ $3.69 Million |
-- |
About Nanologica AB
Nanologica AB (publ), a life science tools company, develops, manufactures, and sells nanoporous silica particles in China, India, Turkey, the United States, and internationally. The company offers NLAB Saga, a silica-based purification media for preparative chromatography that is developed for the purification of peptide drugs, such as insulin and GLP-1 analogues; NLAB Idun, an ion exchange prod… Read more